Genetics

Aevi Genomic Medicine released the company’s financial results for the first quarter of 2017 and announced it will be moving forward with a Phase 2 clinical trial of AEVI-001.

Aevi Genomic Medicine (NASDAQ:GNMX) released the company’s financial results for the first quarter of 2017 and announced it will be moving forward with a Phase 2 clinical trial of AEVI-001.
As quoted in the press release:

“Following additional analysis of the SAGA trial, we remain positive about the genetic subset of patients identified that demonstrate a clear and statistically significant response to AEVI-001,” said Mike Cola, CEO of Aevi Genomic Medicine. “This discovery will allow us to move forward with the development of AEVI-001 in ADHD, and potentially other neurodevelopmental disorders in the future, including Autism Spectrum Disorder. We look forward to initiating the Phase 2 trial of AEVI-001 in patients with the identified genetic subset during the second half of 2017 and anticipate announcing top-line data in mid-2018.”

Click here to read the full press release.

Source: www.newswire.ca

Featured

MARKETS

Markets
TSX20595.89+4.91
TSXV846.29-0.92
DOW34168.09-129.64
S&P 5004349.93-6.52
NASD13542.12+2.82
ASX6961.60-177.90

COMMODITIES

Commodities
Gold1815.27-6.60
Silver23.26-0.31
Copper4.44-0.07
Palladium2316.99-2.02
Platinum1023.32-11.39
Oil86.74-0.61
Heating Oil2.68-0.01
Natural Gas4.26-0.02

DOWNLOAD FREE REPORTS

×